The schedule kicks off at the Cantor Global Healthcare Conference on September 11, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on September 14. The firm concludes its September appearances at the Bernstein 3rd Annual Healthcare Forum on September 23. Investors can access a live webcast of the Morgan Stanley session directly through the company’s investor relations portal, with replays provided after the event concludes.
Viking Therapeutics Sets September Investor Tour
Viking Therapeutics is hitting the investor circuit this September, with management slated to headline three major healthcare conferences in New York. The San Diego-based biopharmaceutical company plans to showcase its metabolic pipeline through a series of fireside chats and private meetings with institutional stakeholders throughout the month.
These appearances arrive as Viking continues to push its clinical-stage portfolio, centered on the dual GLP-1 and GIP receptor agonist VK2735. Currently in Phase 3 trials for obesity, the drug remains the focal point of the company's efforts to secure a foothold in the weight management market. Beyond its lead program, management is also progressing with VK3019 and the liver disease candidate VK2809, both of which serve as secondary pillars in the company's long-term growth narrative.
Comments (0)
No comments yet. Be the first!